Damora Therapeutics (DMRA) Other Non-Current Liabilities (2024 - 2026)
Damora Therapeutics (DMRA) posted Other Non-Current Liabilities of $27000.0 for Q1 2026, down 66.67% on a QoQ basis from $81000.0 in Q4 2025, and down 40.0% year-over-year from $45000.0 in Q1 2025.
Damora Therapeutics (DMRA) Other Non-Current Liabilities (2024 - 2026) Analysis & Trends
Damora Therapeutics' Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $27000.0 for Q1 2026.
- Quarterly Other Non-Current Liabilities fell 40.0% year-over-year to $27000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27000.0 (down 40.0% YoY) and the FY2025 annual result came in at $81000.0, up 88.37% from the prior year.
- Other Non-Current Liabilities was $27000.0 for Q1 2026 at Damora Therapeutics, down from $81000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $81000.0 in Q4 2025 and bottomed at $27000.0 in Q1 2026.
- A 3-year average of $49000.0 and a median of $47000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Other Non-Current Liabilities jumped 88.37% — and 2026, when it tumbled 40.0%.
- Damora Therapeutics' Other Non-Current Liabilities stood at $43000.0 in 2024, then soared by 88.37% to $81000.0 in 2025, then plunged by 66.67% to $27000.0 in 2026.
- Business Quant data shows DMRA's Other Non-Current Liabilities at $27000.0 in Q1 2026, $81000.0 in Q4 2025, and $49000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27,000.00 |
| Dec 31, 2025 | 81,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Jun 30, 2025 | 49,000.00 |
| Mar 31, 2025 | 45,000.00 |
| Dec 31, 2024 | 43,000.00 |